Synch is proud to have assisted Innovestor Life Science Fund and Hadean Ventures in their latest investment in Gesynta Pharma.
The SEK 304 million secured in the funding round will be used by Gesynta Pharma to drive the development of vipoglanstat, a drug candidate with the potential to revolutionize the treatment of endometriosis, a painful inflammatory disease that affects 190 million women globally.
With vipoglanstat, which has shown promising results in preclinical studies, Gesynta Pharma hopes to offer a new, effective and safe treatment method.
Synch look forward to following the success of our clients and Gesynta Pharma in their work to improve the quality of life for women affected by endometriosis.
Synch is a business-oriented law firm with innovation, intellectual property and technology at its heart. Our mission is to bring calm to any legal question, no matter the challenge. We do this by using our curiosity to deeply understand our client's challenges and fully grasp their needs, applying a combination of our knowledge, experience, and the best use of technology through advisory services and packaged solutions.
Synch's team consisted of Andreas Börjesson, Jens Isakzon, Amila Briga, Clara Löfgren, Therése Gardström, Lina Persson and Kristin Tell.
